We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Calcium Levels Linked to Ovarian Cancer

By LabMedica International staff writers
Posted on 13 Feb 2013
Print article
High blood calcium levels might predict ovarian cancer, the most fatal of the gynecological cancers.

Many ovarian cancers express parathyroid hormone-related protein, which acts to raise calcium levels in serum, which may be a biomarker for ovarian cancer.

Cancer epidemiologists at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) measured total and ionized serum calcium levels using ion-specific electrodes. They were pH-adjusted because the protein binding of calcium is affected by pH; ionized calcium in blood is commonly corrected to standard pH. Serum samples were collected as part of Third National Health and Nutrition Examination Surveys (NHANES III) between 1988 and 1994 from two nationally representative prospective cohorts.

Eleven ovarian cancer deaths were observed over 95,556 person-years of follow-up through December 31, 2006, representing 137,404 ovarian cancer deaths in the United States of America. The range in total serum calcium in cases was 2.14–2.44 mmol/L and for ionized serum calcium was 1.17–1.31 mmol/L. The normal reference range for total serum calcium is approximately 2.17–2.52 mmol/L and 1.12–1.32 mmol/L for ionized serum calcium. In the second cohort, there were eight ovarian cancer cases in over 31,089 person-years of follow-up. The range of total serum calcium was 1.98–2.93 mmol/L. The relative hazard for fatal ovarian cancer was 1.52 per 0.1 mmol/L increase in total serum calcium and 2.44 per 0.1 mmol/L increase in ionized serum calcium.

Gary G. Schwartz, PhD, the lead author of the study, said "One approach to cancer biomarker discovery is to identify a factor that is differentially expressed in individuals with and without cancer and to examine that factor's ability to detect cancer in an independent sample of individuals." His coauthor added, "Everyone's got calcium and the body regulates it very tightly. We know that some rare forms of ovarian cancer are associated with very high calcium, so it's worth considering whether more common ovarian cancers are associated with moderately high calcium."

The authors concluded that this biomarker, the higher levels of calcium in serum, were significantly positively associated with the risk of ovarian cancer in two prospective cohorts. The principal limitation of this study is the small number of cases. Conversely, the study has several strengths: it is prospective, uses population-based data from two nationally representative cohorts, and is the first to study ionized serum calcium. The existence of stored sera from sample sets of women with and without ovarian cancer should facilitate the confirmation or refutation of the association between serum calcium and ovarian cancer. The study was published January 9, 2013, in the journal Gynecologic Oncology.

Related Links:
Wake Forest Baptist Medical Center


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.